This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports fourth-quarter 2019 results.
Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study
by Zacks Equity Research
Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.
Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal
by Zacks Equity Research
Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.
Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data
by Zacks Equity Research
It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.
Incyte (INCY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Incyte (INCY) closed at $76.46 in the latest trading session, marking a +0.51% move from the prior day.
Lilly's Olumiant Meets Primary Goal in Dermatitis Study
by Zacks Equity Research
Eli Lilly (LLY) and partner Incyte's Olumiant meets primary endpoint in atopic dermatitis in a late-stage study.
Incyte (INCY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Incyte (INCY) closed at $76.53 in the latest trading session, marking a -0.79% move from the prior day.
Incyte's Application for Pemigatinib Gets EMA's Validation
by Zacks Equity Research
The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data
by Zacks Equity Research
A low-key week for the biotech sector, with a few pipeline and regulatory updates.
Company News For Jan 6, 2020
by Zacks Equity Research
Companies In The News Are: CANF, LW, INCY, NOVN
Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study
by Zacks Equity Research
Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.
Incyte (INCY) Stock Moves -0.44%: What You Should Know
by Zacks Equity Research
In the latest trading session, Incyte (INCY) closed at $88.39, marking a -0.44% move from the previous day.
Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance
by Zacks Equity Research
Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.
Has Incyte (INCY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (INCY) Outperforming Other Medical Stocks This Year?
Incyte (INCY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Incyte (INCY) closed at $90.10 in the latest trading session, marking a -1.14% move from the prior day.
Biotech Stock Outlook: M&A Activity Retains Growth Streak
by Ekta Bagri
The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.
Here's Why Momentum Investors Will Love Incyte (INCY)
by Zacks Equity Research
Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Moving Average Crossover Alert: Incyte
by Zacks Equity Research
Incyte is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Why Is Incyte (INCY) Up 12.5% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.
Merck's Keytruda Gets Nod in China for Difficult Lung Cancer
by Zacks Equity Research
Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.
Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.
Incyte (INCY) Is Up 1.88% in One Week: What You Should Know
by Zacks Equity Research
Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals